(SLGN) Silgan Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8270481091
Stock:
Total Rating 36
Risk 88
Buy Signal 0.14
| Risk 5d forecast | |
|---|---|
| Volatility | 24.8% |
| Relative Tail Risk | -9.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -21.82 |
| Character TTM | |
|---|---|
| Beta | 0.528 |
| Beta Downside | 0.814 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.70% |
| CAGR/Max DD | -0.07 |
EPS (Earnings per Share)
Revenue
Description: SLGN Silgan Holdings
Silgan Holdings Inc., together with its subsidiaries, manufactures and sells rigid packaging solutions for consumer goods products in the United States and internationally. It operates through three segments: Dispensing and Specialty Closures, Metal Containers, and Custom Containers. The company offers integrated dispensing packaging solutions, and proprietary metal and plastic specialty closures, as well as capping/sealing equipment and detection systems for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden markets. It also provides steel and aluminum containers used by processors and packagers for food products, such as pet food, vegetables and fruits, soup, proteins, and other miscellaneous food products, as well as general line metal containers for products, including promotional products. In addition, the company offers custom designed high density polyethylene, and polyethylene terephthalate, containers; thermoformed barrier and non-barrier bowls, and trays for shelf-stable food products; and plastic closures, caps, sifters and fitments for food and household products. It markets its products primarily through direct sales force, as well as through a network of distributors, and an online shopping catalog. The company was founded in 1987 and is headquartered in Norwalk, Connecticut.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 312.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.06 > 1.0 |
| NWC/Revenue: 13.37% < 20% (prev 4.70%; Δ 8.67% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.29b > Net Income 312.8m |
| Net Debt (3.27b) to EBITDA (673.6m): 4.85 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.8m) vs 12m ago -1.40% < -2% |
| Gross Margin: 16.94% > 18% (prev 0.17%; Δ 1677 % > 0.5%) |
| Asset Turnover: 77.33% > 50% (prev 68.20%; Δ 9.13% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBITDA TTM 673.6m / Interest Expense TTM 190.6m) |
Altman Z'' 2.56
| A: 0.10 (Total Current Assets 2.75b - Total Current Liabilities 1.82b) / Total Assets 9.40b |
| B: 0.38 (Retained Earnings 3.61b / Total Assets 9.40b) |
| C: 0.05 (EBIT TTM 430.4m / Avg Total Assets 8.99b) |
| D: 0.32 (Book Value of Equity 2.27b / Total Liabilities 7.12b) |
| Altman-Z'' Score: 2.56 = A |
Beneish M -3.10
| DSRI: 0.84 (Receivables 589.4m/594.3m, Revenue 6.95b/5.85b) |
| GMI: 1.02 (GM 16.94% / 17.28%) |
| AQI: 1.03 (AQ_t 0.45 / AQ_t-1 0.44) |
| SGI: 1.19 (Revenue 6.95b / 5.85b) |
| TATA: -0.10 (NI 312.8m - CFO 1.29b) / TA 9.40b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of SLGN shares?
As of February 27, 2026, the stock is trading at USD 47.87 with a total of 555,847 shares traded.
Over the past week, the price has changed by -0.75%, over one month by +10.68%, over three months by +21.87% and over the past year by -11.66%.
Over the past week, the price has changed by -0.75%, over one month by +10.68%, over three months by +21.87% and over the past year by -11.66%.
Is SLGN a buy, sell or hold?
Silgan Holdings has received a consensus analysts rating of 4.42.
Therefore, it is recommended to buy SLGN.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SLGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.3 | 15.5% |
| Analysts Target Price | 55.3 | 15.5% |
SLGN Fundamental Data Overview February 21, 2026
P/E Trailing = 17.7667
P/E Forward = 12.8041
P/S = 0.7917
P/B = 2.2604
P/EG = 0.8384
Revenue TTM = 6.95b USD
EBIT TTM = 430.4m USD
EBITDA TTM = 673.6m USD
Long Term Debt = 3.81b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.13b USD (from shortLongTermDebt, two quarters ago)
Debt = 4.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.27b USD (from netDebt column, last quarter)
Enterprise Value = 8.40b USD (5.13b + Debt 4.35b - CCE 1.08b)
Interest Coverage Ratio = 2.26 (Ebit TTM 430.4m / Interest Expense TTM 190.6m)
EV/FCF = 8.59x (Enterprise Value 8.40b / FCF TTM 977.7m)
FCF Yield = 11.64% (FCF TTM 977.7m / Enterprise Value 8.40b)
FCF Margin = 14.06% (FCF TTM 977.7m / Revenue TTM 6.95b)
Net Margin = 4.50% (Net Income TTM 312.8m / Revenue TTM 6.95b)
Gross Margin = 16.94% ((Revenue TTM 6.95b - Cost of Revenue TTM 5.78b) / Revenue TTM)
Gross Margin QoQ = 17.21% (prev 16.29%)
Tobins Q-Ratio = 0.89 (Enterprise Value 8.40b / Total Assets 9.40b)
Interest Expense / Debt = 1.10% (Interest Expense 47.7m / Debt 4.35b)
Taxrate = 29.95% (123.3m / 411.7m)
NOPAT = 301.5m (EBIT 430.4m * (1 - 29.95%))
Current Ratio = 1.51 (Total Current Assets 2.75b / Total Current Liabilities 1.82b)
Debt / Equity = 1.91 (Debt 4.35b / totalStockholderEquity, last quarter 2.27b)
Debt / EBITDA = 4.85 (Net Debt 3.27b / EBITDA 673.6m)
Debt / FCF = 3.34 (Net Debt 3.27b / FCF TTM 977.7m)
Total Stockholder Equity = 2.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 312.8m / Total Assets 9.40b)
RoE = 14.13% (Net Income TTM 312.8m / Total Stockholder Equity 2.21b)
RoCE = 7.14% (EBIT 430.4m / Capital Employed (Equity 2.21b + L.T.Debt 3.81b))
RoIC = 4.27% (NOPAT 301.5m / Invested Capital 7.07b)
WACC = 4.61% (E(5.13b)/V(9.48b) * Re(7.86%) + D(4.35b)/V(9.48b) * Rd(1.10%) * (1-Tc(0.30)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.52%
[DCF] Terminal Value 87.00% ; FCFF base≈770.3m ; Y1≈825.8m ; Y5≈1.00b
[DCF] Fair Price = 250.6 (EV 29.74b - Net Debt 3.27b = Equity 26.48b / Shares 105.7m; r=5.90% [WACC]; 5y FCF grow 8.09% → 2.90% )
EPS Correlation: -5.24 | EPS CAGR: -3.97% | SUE: 1.15 | # QB: 1
Revenue Correlation: 19.43 | Revenue CAGR: 0.49% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.75 | Chg7d=-0.021 | Chg30d=-0.021 | Revisions Net=-5 | Analysts=11
EPS current Year (2026-12-31): EPS=3.80 | Chg7d=-0.005 | Chg30d=-0.013 | Revisions Net=-4 | Growth EPS=+2.3% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=4.09 | Chg7d=-0.055 | Chg30d=-0.070 | Revisions Net=-3 | Growth EPS=+7.5% | Growth Revenue=+2.1%
[Analyst] Revisions Ratio: -0.56 (2 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.3% (Discount Rate 7.9% - Earnings Yield 5.6%)
[Growth] Growth Spread = +0.4% (Analyst 2.7% - Implied 2.3%)
P/E Forward = 12.8041
P/S = 0.7917
P/B = 2.2604
P/EG = 0.8384
Revenue TTM = 6.95b USD
EBIT TTM = 430.4m USD
EBITDA TTM = 673.6m USD
Long Term Debt = 3.81b USD (from longTermDebt, two quarters ago)
Short Term Debt = 1.13b USD (from shortLongTermDebt, two quarters ago)
Debt = 4.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.27b USD (from netDebt column, last quarter)
Enterprise Value = 8.40b USD (5.13b + Debt 4.35b - CCE 1.08b)
Interest Coverage Ratio = 2.26 (Ebit TTM 430.4m / Interest Expense TTM 190.6m)
EV/FCF = 8.59x (Enterprise Value 8.40b / FCF TTM 977.7m)
FCF Yield = 11.64% (FCF TTM 977.7m / Enterprise Value 8.40b)
FCF Margin = 14.06% (FCF TTM 977.7m / Revenue TTM 6.95b)
Net Margin = 4.50% (Net Income TTM 312.8m / Revenue TTM 6.95b)
Gross Margin = 16.94% ((Revenue TTM 6.95b - Cost of Revenue TTM 5.78b) / Revenue TTM)
Gross Margin QoQ = 17.21% (prev 16.29%)
Tobins Q-Ratio = 0.89 (Enterprise Value 8.40b / Total Assets 9.40b)
Interest Expense / Debt = 1.10% (Interest Expense 47.7m / Debt 4.35b)
Taxrate = 29.95% (123.3m / 411.7m)
NOPAT = 301.5m (EBIT 430.4m * (1 - 29.95%))
Current Ratio = 1.51 (Total Current Assets 2.75b / Total Current Liabilities 1.82b)
Debt / Equity = 1.91 (Debt 4.35b / totalStockholderEquity, last quarter 2.27b)
Debt / EBITDA = 4.85 (Net Debt 3.27b / EBITDA 673.6m)
Debt / FCF = 3.34 (Net Debt 3.27b / FCF TTM 977.7m)
Total Stockholder Equity = 2.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 312.8m / Total Assets 9.40b)
RoE = 14.13% (Net Income TTM 312.8m / Total Stockholder Equity 2.21b)
RoCE = 7.14% (EBIT 430.4m / Capital Employed (Equity 2.21b + L.T.Debt 3.81b))
RoIC = 4.27% (NOPAT 301.5m / Invested Capital 7.07b)
WACC = 4.61% (E(5.13b)/V(9.48b) * Re(7.86%) + D(4.35b)/V(9.48b) * Rd(1.10%) * (1-Tc(0.30)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.52%
[DCF] Terminal Value 87.00% ; FCFF base≈770.3m ; Y1≈825.8m ; Y5≈1.00b
[DCF] Fair Price = 250.6 (EV 29.74b - Net Debt 3.27b = Equity 26.48b / Shares 105.7m; r=5.90% [WACC]; 5y FCF grow 8.09% → 2.90% )
EPS Correlation: -5.24 | EPS CAGR: -3.97% | SUE: 1.15 | # QB: 1
Revenue Correlation: 19.43 | Revenue CAGR: 0.49% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.75 | Chg7d=-0.021 | Chg30d=-0.021 | Revisions Net=-5 | Analysts=11
EPS current Year (2026-12-31): EPS=3.80 | Chg7d=-0.005 | Chg30d=-0.013 | Revisions Net=-4 | Growth EPS=+2.3% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=4.09 | Chg7d=-0.055 | Chg30d=-0.070 | Revisions Net=-3 | Growth EPS=+7.5% | Growth Revenue=+2.1%
[Analyst] Revisions Ratio: -0.56 (2 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.3% (Discount Rate 7.9% - Earnings Yield 5.6%)
[Growth] Growth Spread = +0.4% (Analyst 2.7% - Implied 2.3%)